William Blair initiated coverage of Inari Medical with an Outperform rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- Inari Medical downgraded to Hold from Buy at Needham
- Inari Medical price target raised to $60 from $47 at Truist
- Inari Medical price target raised to $60 from $55 at Morgan Stanley
- Piper says Sight Sciences, Paragon 28 codes rated higher in CMS proposal
- Class Action Lawsuit Against Inari Medical, Inc. (NASDAQ:NARI)
Questions or Comments about the article? Write to editor@tipranks.com